Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Other Non-Current Assets (2016 - 2025)

Avalo Therapeutics' Other Non-Current Assets history spans 12 years, with the latest figure at $210000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 60.31% year-over-year to $210000.0; the TTM value through Dec 2025 reached $210000.0, up 60.31%, while the annual FY2025 figure was $210000.0, 60.31% up from the prior year.
  • Other Non-Current Assets reached $210000.0 in Q4 2025 per AVTX's latest filing, roughly flat from $210000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.0 million in Q4 2021 to a low of $131000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $205000.0, with a median of $140000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: plummeted 86.9% in 2022, then soared 60.31% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.0 million in 2021, then tumbled by 86.9% to $131000.0 in 2022, then changed by 0.0% to $131000.0 in 2023, then changed by 0.0% to $131000.0 in 2024, then skyrocketed by 60.31% to $210000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Other Non-Current Assets are $210000.0 (Q4 2025), $210000.0 (Q3 2025), and $210000.0 (Q2 2025).